SOHO 2024: Focus on Myeloma
Advertisement
Advertisement
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Patients with double-hit or triple-hit MM had significantly poorer outcomes compared to those with single-hit MM.
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.
Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD.
Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS.
The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM.
The addition of daratumumab to VRd induction and consolidation induced higher rates of MRD negativity.
A single tocilizumab dose prior to initiation of teclistamab therapy effectively reduced the incidence of CRS.
Treatment with CELMoDs showed promising efficacy but high rates of neutropenia in patients with multiple myeloma.
Cilta-cel improved outcomes versus standard or care in myeloma, with a safety profile consistent with CAR-T therapies.
Patients in the cohort of a post-hoc analysis of the phase III CARTITUDE-4 trial received two different bridging regimens.
A retrospective study compared results from daratumumab plus carfilzomib plus dexamethasone in different lines of therapy.
Patients in the trial subanalysis had previously received an immunomodulatory agent, proteasome inhibitor, and daratumumab.
The review also compiled an array of proposed solutions to meet the needs of patients and caregivers.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.